Eli Lilly and Company (LLY)vsSensus Healthcare Inc (SRTS)
LLY
Eli Lilly and Company
$1,105.00
+1.80%
HEALTHCARE · Cap: $905.79B
SRTS
Sensus Healthcare Inc
$3.09
-2.83%
HEALTHCARE · Cap: $46.92M
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 262796% more annual revenue ($72.25B vs $27.48M). LLY leads profitability with a 35.0% profit margin vs -28.1%. LLY earns a higher WallStSmart Score of 78/100 (B+).
LLY
Strong Buy78
out of 100
Grade: B+
SRTS
Hold35
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for LLY.
Margin of Safety
-6.3%
Fair Value
$4.48
Current Price
$3.09
$1.39 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 81 in profit
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 49.4%
Revenue surging 55.5% year-over-year
Earnings expanding 169.9% YoY
Reasonable price relative to book value
Earnings expanding 433.3% YoY
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Areas to Watch
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 31.6x book value
Smaller company, higher risk/reward
Weak financial health signals
ROE of -17.1% — below average capital efficiency
Revenue declined 62.2%
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 35.0% and operating margin at 49.4%. Revenue growth of 55.5% demonstrates continued momentum.
Bull Case : SRTS
The strongest argument for SRTS centers on Price/Book, EPS Growth, Debt/Equity.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book.
Bear Case : SRTS
The primary concerns for SRTS are Market Cap, Piotroski F-Score, Return on Equity.
Key Dynamics to Monitor
LLY profiles as a growth stock while SRTS is a turnaround play — different risk/reward profiles.
SRTS carries more volatility with a beta of 1.19 — expect wider price swings.
LLY is growing revenue faster at 55.5% — sustainability is the question.
LLY generates stronger free cash flow (3.0B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (78/100 vs 35/100), backed by strong 35.0% margins and 55.5% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Sensus Healthcare Inc
HEALTHCARE · MEDICAL DEVICES · USA
Sensus Healthcare, Inc. manufactures, distributes and markets superficial radiation therapy devices to healthcare providers worldwide. The company is headquartered in Boca Raton, Florida.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?